Immuno-Oncology

Lung cancer is the leading cause of cancer-related deaths among men and women in the United States, despite being the second most commonly diagnosed cancer.

Pembrolizumab provided durable activity for previously treated patients with mucosal melanoma, according to data coming out of 3 clinical trials.

Richard Finn, MD, associate professor of Medicine at the UCLA David Geffen School of Medicine, discusses studies of pembrolizumab (Keytruda) in patients with previously untreated hepatocellular carcinoma (HCC).

Daniel P. Petrylak, MD, professor of Medicine and Urology, Yale Cancer Center, discusses immune checkpoint inhibitors that are currently being evaluated for the treatment of patients with bladder cancer.

Immuno-oncology drugs have the potential to improve the level of care in many respects, but they bring with them a host of problems related to implementation that require a completely new set of strategies.

Tian Zhang, MD, a medical instructor in the Department of Medicine, Duke University School of Medicine, discusses some of the challenges associated with administering vaccines to patients with renal cell carcinoma.

Geoffrey Sklar, MD, Chief Medical Officer, Chesapeake Urology Associates, discusses the potential of immunotherapy agents in the treatment of patients with bladder cancer.

Jonathan E. Rosenberg, MD, medical oncologist, Memorial Sloan Kettering Cancer Center, discusses the potential that immunotherapy has in the frontline setting for patients with bladder cancer.

Robert J. Motzer, MD, medical oncologist at Memorial Sloan Kettering Cancer Center, 2016 Giant of Cancer Care in Genitourinary Cancer, discusses the explosion of immunotherapy in the landscape of renal cell carcinoma (RCC).

Gabriela Chiorean, MD, associate professor of Medicine at the University of Washington, discusses adverse events of the phase I study of combination therapies for patients with pancreatic cancer.

Neeraj Agarwal, MD, discusses a trend of underreporting and underemphasizing toxicities associated with PD-1 inhibitors in the treatment of patients with renal cell carcinoma.

The promising antitumor activity of nivolumab in patients with microsatellite instability-high metastatic colorectal cancer was sustained in an update of the phase II CheckMate-142 trial.

Sumanta Kumar Pal, MD, medical oncologist, assistant clinical professor, Department of Medical Oncology and Therapeutics Research, co-director, Kidney Cancer Program, City of Hope, discusses the potential with immunotherapy in the preoperative setting for patients with renal cell carcinoma.

Elizabeth Plimack, MD, discusses updated data from the pivotal CheckMate-025 trial, which compared the use of nivolumab with everolimus in the treatment of patients with metastatic renal cell carcinoma.

Tanguy I. Seiwert, MD, assistant professor of Medicine, University of Chicago Medicine, discusses the next steps researchers are taking to improve survival outcomes for patients with head and neck cancer.

Tian Zhang, MD, discusses the development of vaccines to treat patients with renal cell carcinoma.

Ghassan K. Abou-Alfa, MD, medical oncologist, Memorial Sloan Kettering Cancer Center, discusses ongoing studies investigating immunotherapy in hepatocellular carcinoma.

Ian Chau, MD, consultant medical oncologist, Royal Marsden Hospital, discusses interim safety and clinical activity results in patients with advanced gastric or gastroesophageal junction adenocarcinoma from a multi-cohort phase I study of ramucirumab plus pembrolizumab.

Bristol-Myers Squibb and AstraZeneca have each announced separate delays in the development of PD-1 and CTLA-4 inhibitor combinations as first-line therapies for patients with advanced or metastatic non–small cell lung cancer.

David F. McDermott, MD, discusses ongoing efforts to improve outcomes in advanced renal cell carcinoma through combination anti–VEGF/PD-1 regimens.

A combination regimen of pembrolizumab plus ramucirumab demonstrated modest activity in patients with previously treated gastric or gastroesophageal juncture cancer.

Hossein Borghaei, DO, chief, Division of Thoracic Medical Oncology, director, Lung Cancer Risk Assessment, associate professor, Department of Hematology/Oncology, Fox Chase Cancer Center, discusses how physicians can help patients with lung cancer feel more comfortable reporting adverse events (AEs) associated with immunotherapy.

Treatment with nivolumab reduced the risk of death by 37% compared with placebo for patients with advanced gastric or gastroesophageal junction cancer following second or later-line chemotherapy.

Neeraj Agarwal, associate professor in the Division of Oncology, Department of Medicine, director of the Genitourinary Medical Oncology Program, Huntsman Cancer Institute at the University of Utah, discusses some of the adverse events (AEs) associated with checkpoint inhibitors for the treatment of patients with renal cell carcinoma (RCC).

Michael J. Overman, MD, medical oncologist, Department of Gastrointestinal Medical Oncology, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, discusses updated results from the CheckMate 142 trial, which investigated nivolumab (Opdivo) alone or in combination with ipilimumab (Yervoy) in patients with DNA mismatch repair deficient/microsatellite instability high (MSI-H) metastatic colorectal cancer (mCRC).

Roy S. Herbst, MD, PhD, ensign professor of Medicine, professor of Pharmacology, chief of Medical Oncology, associate director for Translational Research, Yale Cancer Center and Smilow Cancer Hospital, discusses combination therapies for patients with lung cancer.

Paul A. Bunn, Jr., MD, professor of Medicine, head of the Division of Medical Oncology at the University of Colorado, discusses combining immunotherapy with chemotherapy and targeted agents in lung cancer.

Steven Horwitz, MD, associate attending physician at Memorial Sloan Kettering Cancer Center, discusses some of the ongoing clinical trials being explored in T-cell lymphoma.

Robert J. Motzer, MD, attending physician, Genitourinary Oncology Service, Memorial Sloan Kettering Cancer Center, and professor of Medicine, Weill Medical College, Cornell University, discusses the FDA approval of nivolumab (Opdivo) versus everolimus (Afinitor) for patients with advanced renal cell carcinoma (RCC).

Since the FDA approval of nivolumab in May 2016, researchers continue to explore agent as well as its fellow PD-1 inhibitor, pembrolizumab, in various treatment settings for patients with Hodgkin lymphoma.